Vertex Pharmaceuticals Incorporated
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 72
- Registration Number
- NCT05818852
- Locations
- πΊπΈ
ICON Lenexa, Lenexa, Kansas, United States
πΊπΈICON Salt Lake City, Salt Lake City, Utah, United States
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 17
- Registration Number
- NCT05791201
- Locations
- π¨π
Hopiteaux Universitaires de Geneve, Geneve, Switzerland
π¨π¦Montreal Clinical Research Institute, Montreal, Canada
πΊπΈUHealth Diabetes Research Institute, Miami, Florida, United States
A Phase 1, First-in-human Study of VX-668
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 114
- Registration Number
- NCT05727800
- Locations
- πΊπΈ
ICON Salt Lake City, Salt Lake City, Utah, United States
πΊπΈCelerion - Tempe, Tempe, Arizona, United States
πΊπΈUniversity of Florida, Gainesville, Florida, United States
Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 38
- Registration Number
- NCT05704556
- Locations
- πΊπΈ
Southwest Houston Research, Ltd, Houston, Texas, United States
πΊπΈClinical Pharmacology of Miami, LLC, Miami, Florida, United States
πΊπΈGenesis Clinical Research, Tampa, Florida, United States
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT05668741
- Locations
- πΈπͺ
Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈMiller Children's Hospital / Long Beach Memorial, Long Beach, California, United States
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 258
- Registration Number
- NCT05661734
- Locations
- πΊπΈ
Cypress Surgery Center, Wichita, Kansas, United States
πΊπΈMart Medical Research Group LLC, South Miami, Florida, United States
πΊπΈCenter for Orthopaedic Reconstruction and Excellence, Jenks, Oklahoma, United States
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 192
- Registration Number
- NCT05660538
- Locations
- πΊπΈ
University Clinical Investigators, Tustin, California, United States
πΊπΈVelocity Clinical Research - Medford, Medford, Oregon, United States
πΊπΈSynexus - Orlando, Orlando, Florida, United States
A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 70
- Registration Number
- NCT05653323
- Locations
- π¬π§
MAC Clinical Research, Manchester, United Kingdom
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 20
- Registration Number
- NCT05643495
- Locations
- πΊπΈ
University of Kansas Medical Center, Kansas City, Kansas, United States
πΊπΈUniversity of Florida, Gainesville, Florida, United States
πΊπΈThe University of Iowa Hospitals and Clinics: Adult Pulmonary Clinic, Iowa City, Iowa, United States
Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 31
- Registration Number
- NCT05635110
- Locations
- π¦πΊ
CMAX Clinical Research, Adelaide, Australia